NSABP B-40 (CINJ 040701): A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Gemcitabine (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin
- Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer
- Focus Therapeutic Use
- 14 Dec 2019 Results (N= 15,457), a metanalysis of prospective randomized trials assessing efficacy of Capecitabine as a part of neo adjuvant or adjuvant therapy in patients with early breast cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 12 Sep 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 03 Jun 2016 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017.